নিউরোএন্ডোক্রাইন টিউমার
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
কোথায় যেতে হবে
এই ট্রায়ালের জন্য ভারতের 2টি হাসপাতালে রোগী নেওয়া হচ্ছে।
রেজিস্ট্রির সারসংক্ষেপ (টেকনিক্যাল)
Neuroendocrine tumours (NETs), better defined as neoplasms (NENs), are a heterogeneous group of neoplasms that range from well-differentiated tumours to more aggressive carcinomas. Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the established standard of care for patients with well-differentiated metastatic or locally advanced GEP-NETs. It has demonstrated a significant improvement in outcomes compared to Octreotide LAR, both as a first-line and second-line treatment approach, following the results of NETTER-1 and NETTER-2 trials, respectively. ENETS guidelines rec…
Sponsor: Tata Memorial Hospital
NCT07185672 on ClinicalTrials.gov
Last updated on the registry 22 Sep 2025 · read by us 20 Oct 2026